NASDAQ:TCBP TC Biopharm (TCBP) Stock Price, News & Analysis $0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock About TC Biopharm Stock (NASDAQ:TCBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TC Biopharm alerts:Sign Up Key Stats Today's Range$0.50▼$1.5450-Day Range$0.50▼$2.2352-Week Range$0.50▼$480.00Volume5.33 million shsAverage Volume134,628 shsMarket Capitalization$279,210.00P/E RatioN/ADividend YieldN/APrice Target$48.00Consensus RatingBuy Company OverviewTC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Read More… TC Biopharm Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreTCBP MarketRank™: TC Biopharm scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTC Biopharm has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTC Biopharm has received no research coverage in the past 90 days.Read more about TC Biopharm's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTC Biopharm has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TCBP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTC Biopharm does not currently pay a dividend.Dividend GrowthTC Biopharm does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for TCBP. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for TCBP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TC Biopharm insiders have not sold or bought any company stock.Percentage Held by Insiders15.44% of the stock of TC Biopharm is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.25% of the stock of TC Biopharm is held by institutions.Read more about TC Biopharm's insider trading history. Receive TCBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address TCBP Stock News HeadlinesTCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T CellsApril 9, 2025 | finance.yahoo.comTC BioPharm: TCBP Announces Transition from Nasdaq to OTC MarketsMarch 24, 2025 | finanznachrichten.deHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 2, 2025 | Brownstone Research (Ad)TC BioPharm to be delisted from Nasdaq, moves to OTC MarketsMarch 23, 2025 | uk.investing.comTC Biopharm announces transition to OTC Markets from NasdaqMarch 22, 2025 | markets.businessinsider.comTC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses FrustrationMarch 21, 2025 | msn.comTC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting NoticeMarch 21, 2025 | tipranks.comTCBP Announces Transition from Nasdaq to OTC MarketsMarch 21, 2025 | prnewswire.comSee More Headlines TCBP Stock Analysis - Frequently Asked Questions How have TCBP shares performed this year? TC Biopharm's stock was trading at $10.32 on January 1st, 2025. Since then, TCBP shares have decreased by 93.4% and is now trading at $0.6810. View the best growth stocks for 2025 here. When did TC Biopharm's stock split? TC Biopharm shares reverse split on the morning of Monday, February 10th 2025. The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did TC Biopharm IPO? TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at $4.25 per share. EF Hutton acted as the underwriter for the IPO. How do I buy shares of TC Biopharm? Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TC Biopharm own? Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), Exxon Mobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP). Company Calendar Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCBP CIK1872812 Webwww.tcbiopharm.com Phone44-14-1433-7557FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$48.00 High Stock Price Target$48.00 Low Stock Price Target$48.00 Potential Upside/Downside+6,948.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.67 Current Ratio1.12 Quick RatioN/A Sales & Book Value Annual Sales$4.76 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book Value$519.58 per share Price / Book0.00Miscellaneous Outstanding Shares410,000Free Float28,000Market Cap$279,210.00 OptionableNot Optionable Beta0.01 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:TCBP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share TC Biopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.